Periodic Reporting for period 4 - THERACAN (Novel therapeutic strategies to treat pancreatic and lung cancer)

A quarter of all solid tumors harbor a mutation in the KRAS oncogenes. Despite the identification of these mutations over 30 years ago, no selective drugs have been approved to treat these malignancies. Our aim is to identify and validate targets with potential therapeutic...